References
- Toledo-Pereyra LH, Toledo AH, Walsh J, et al. Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant. 2004;2:174–177.
- Carden DL, Granger DN. Pathophysiology of ischaemia reperfusion injury. J Pathol. 2000;190:255–266.
- Granger DN, Benoit JN, Suzuki M, et al. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol. 1989;257:G683–688.
- Schmid-Schonbein GW. Capillary plugging by granulocytes and the no-reflow phenomenon in the microcirculation. Fed Proc. 1987;46:2397–2401.
- Inoue N, Ramasamy S, Fukai T, et al. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. Circ Res. 1996;79:32–37.
- Menger MD, Laschke MW, Amon M, et al. Experimental models to study microcirculatory dysfunction in muscle ischemia-reperfusion and osteomyocutaneous flap transfer. Langenbecks Arch Surg. 2003;388:281–290.
- Nolte D, Menger MD, Messmer K. Microcirculatory models of ischaemia-reperfusion in skin and striated muscle. Int J Microcirc Clin Exp. 1995;15(Suppl 1):9–16.
- Szabó C, Thiemermann C. Invited opinion: role of nitric oxide in hemorrhagic, traumatic, and anaphylactic shock and thermal injury. Shock. 1994;2:145–155.
- Gladwin MT, Raat NJ, Shiva S, et al. Nitrite as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2026–35.
- Dezfulian C, Raat N, Shiva S, et al. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res. 2007 Jul 15;75(2):327–338.
- Lefer DJ. Emerging role of nitrite in myocardial protection. Arch Pharm Res. 2009 Aug;32(8):1127–1138.
- Abe Y, Hines I, Zibari G, et al. Hepatocellular protection by nitric oxide or nitrite in ischemia and reperfusion injury. Arch Biochem Biophys. 2009 Apr 15;484(2):232–237.
- Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005 May;115(5):1232–1240.
- Wang WZ, Fang XH, Stephenson LL, et al. Nitrite attenuates ischemia-reperfusion-induced microcirculatory alterations and mitochondrial dysfunction in the microvasculature of skeletal muscle. Plast Reconstr Surg. 2011 Oct;128(4):279e–287e.
- Murata I, Nozaki R, Ooi K, et al. Nitrite reduces ischemia/reperfusion-induced muscle damage and improves survival rates in rat crush injury model. J Trauma Acute Care Surg. 2012 Jun;72(6):1548–1554.
- Jung KH, Chu K, Ko SY, et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke. 2006 Nov;37(11):2744–2750.
- Campelo MW, Oriá RB, Lopes LG, et al. Preconditioning with a novel metallopharmaceutical NO donor in anesthetized rats subjected to brain ischemia/reperfusion. Neurochem Res. 2012 Apr;37(4):749–758.
- Basireddy M, Isbell TS, Teng X, et al. Effects of sodium nitrite on ischemia-reperfusion injury in the rat kidney. Am J Physiol Renal Physiol. 2006 Apr;290(4):F779–86.
- Milsom AB, Patel NS, Mazzon E, et al. Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemia-reperfusion injury in mice. Nitric Oxide. 2010 Feb 15;22(2):141–148.
- Oronsky B, Fanger GR, Oronsky N, et al. The implications of hyponitroxia in cancer. Transl Oncol. 2014 Apr;7(2):167–173.
- Oronsky BT, Knox SJ, Scicinski JJ. Is Nitric Oxide (NO) the last word in radiosensitization? A review. Transl Oncol. 2012 Apr;5(2):66–71.
- Carter CA, Oronsky BT, Caroen SZ, et al. RRx-001 in refractory small-cell lung carcinoma: a case report of a partial response after a third reintroduction of platinum doublets. Case Rep Oncol. 2016 Mar 11;9(1):171–176.
- Scicinski J, Oronsky B, Ning S, et al. NO to cancer: the complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015 Dec;6:1–8.
- Fens MH, Larkin SK, Oronsky B, et al. The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions. PLoS One. 2014 Jul 9; 9(7):e101626.
- Yalcin O, Oronsky B, Carvalho LJ, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218.
- Brouse C, Ortiz D, Su Y, et al. Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. Asian J Transfus Sci. 2015 Jan-Jun;9(1):55–60.
- Oronsky B, Scicinski J, Ning S, et al. RRx-001, A novel dinitroazetidine radiosensitizer. Invest New Drugs. 2016 Feb 3;34:371–377. Epub ahead of print.
- Oronsky B, Scicinski J, Ning S, et al. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer and immunosensitizer that inhibits glucose 6-phosphate dehydrogenase in human tumor cells. Discov Med. 2016 Apr;21(116):251–265.
- Ning S, Bednarski M, Oronsky B, et al. Dintroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012;15(72):2600–2608.
- Fens MHAM, Larkin SK, Morris CR, et al. NO or No NO, increased reduction of nitrite to nitric oxide by modified red blood cells. Blood (ASH Annual Meeting Abstracts). 2011;118:2125.
- Colantuoni A, Bertuglia S, Intaglietta M. Quantitation of rhythmic diameter changes in arterial microcirculation. Am J Physiol. 1984;246:H508–H517.
- Endrich B, Asaishi K, Götz A, et al. Technical report: A new chamber technique for microvascular studies in unanaes-thetized hamsters. Res Exp Med. 1980;177:125–134.
- Cabrales P, Nacharaju P, Manjula BN, et al. Early difference in tissue pH and microvascular hemodynamics in hemorrhagic shock resuscitation using peg-albumin and hydroxyethyl starch based plasma expanders. Shock. 2005;24:66–73.
- Tsai AG, Friesenecker B, McCarthy M, et al. Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skin fold model. Am J Physiol. 1998;275:H2170–H2180.
- Friesenecker B, Tsai AG, Instaglietta M. Capillary perfusion during ischemia-reperfusion in subcutaneous connective tis- sue and skin muscle. Am J Physiol. 1994;267:H2204–2212.
- Intaglietta M, Silverman NR, Tompkins WR. Capillary flow velocity measure- ments in vivo and in situ by television methods. Microvasc Res. 1975;10:165–179.
- Cabrales P, Tsai AG, Intaglietta M. Exogenous nitric oxide induces protection during hemorrhagic shock. Resuscitation. 2009;80:707–712.
- Childs EW, Udobi KF, Wood JG, et al. In vivo visualization of reactive oxidants and leukocyte-endothelial adherence following hemorrhagic shock. Shock. 2002;18:423–427.
- Scicinski J, Oronsky B, Taylor M, et al. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anti-cancer agent. Drug Metab Dispos. 2012;40:1810–1816.
- Cabrales P, Tsai AG, Frangos JA, et al. Role of endothelial nitric oxide in microvascular oxygen delivery and consumption. Free Radic Biol Med. 2005;39:1229–1237.
- Crawford JH, Isbell TS, Huang Z, et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood. 2006;107:566–574.
- Paxian M, Keller SA, Huynh TT, et al. Perflubron emulsion improves hepatic microvascular integrity and mito- chondrial redox state after hemorrhagic shock. Shock. 2003;20:449–457.
- Baker JE, Boerboom LE, Olinger GN. Age and protection of the ischemic myocardium: is alkaline cardioplegia appropriate? Ann Thorac Surg. 1993;55:747–755.
- Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651–4655.
- Laude K, Thuillez C, Richard V, Reperfusion-induced coronary endothelial injury: A new target for ischemic preconditioning. Exp Clin Cardiol. 2001 Fall;6(3):149–152.
- Shiva S, Gladwin MT. Nitrite mediates cytoprotection after ischemia/reperfusion by modulating mitochondrial function. Basic Res Cardiol. 2009 Mar;104(2):113–119.
- Shiva S, Sack MN, Greer JJ, et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 2007 Sep 3;204(9):2089–2102.
- Reid T, Oronsky B, Scicinski J, et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1133–1142.